Merck MS Drug Fails to Meet Target of Late-Stage Trials

[ad_1]

Merck’s multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials.

The German pharmaceutical company’s phase 3 clinical trials for the drug did not achieve their primary target of reducing annualized relapse rates in people with relapsing multiple sclerosis, it said late Tuesday. The drugmaker was aiming to match the rate of Aubagio, an oral drug for the disease owned by Sanofi.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

[ad_2]

Source link